Search

Copyright of European Journal of Clinical & Experimental Medicine is the property of University of Rzeszow and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

This review presents the current state of knowledge on cotinine, the major metabolite of nicotine. Special attention is paid to the formation of this compound in the organism, its metabolism, application in diagnostic procedures and evaluation of its in vitro and in vivo activities. For many years, cotinine has been used as a biomarker of exposure to tobacco smoke. Currently, this compound is applied in many other studies including the use of cotinine in the treatment of various diseases. Several years ago, Scott et al. patented therapeutic applications of cotinine in chronic and acute inflammation. Cotinine is an interesting compound with a well-known metabolism; therefore there are suggestions for its application in the diagnosis and treatment of certain diseases. [ABSTRACT FROM AUTHOR]

Rho proteins, including RhoA, Rac1 and Cdc42, are members of the Ras superfamily of monomeric GTP-binding proteins, which are well-known regulators of the cytoskeleton. Numerous studies have shown that an intact cytoskeleton is required for cell cycle progression through G1 phase as well as mitosis and cytokinesis. Because of their role in both cytoskeletal rearrangement and mitogenic signaling, Rho family proteins are key mediators of cell cycle progression. In this paper, we review the current state of knowledge concerning the Rho-dependent signaling pathways that regulate the expression of cell cycle regulatory proteins required for G1 phase progression and S phase entry.

This review presents the current state of knowledge on cotinine, the major metabolite of nicotine. Special attention is paid to the formation of this compound in the organism, its metabolism, application in diagnostic procedures and evaluation of its in vitro and in vivo activities. For many years, cotinine has been used as a biomarker of exposure to tobacco smoke. Currently, this compound is applied in many other studies including the use of cotinine in the treatment of various diseases. Several years ago, Scott et al. patented therapeutic applications of cotinine in chronic and acute inflammation. Cotinine is an interesting compound with a well-known metabolism; therefore there are suggestions for its application in the diagnosis and treatment of certain diseases.